Category: News

European startups applying for patents and/or trademarks during their initial seed or early growth stages are up to 10.2 times more likely to secure funding from investors. What’s more, the ownership of European patents and EU trademarks is associated with an even higher advantage, with a rate of securing early-stage funding exceeding five times that of those with only national intellectual property rights. These are the key findings of a new study published jointly by the EPO and EUIPO.
The key findings of the study include:

• On average, 29% of European startups have filed for patents or registered trademarks, though there are significant differences between industry sectors.
• Startups increasingly make use of IP rights as they grow, with a strong focus on European IP rights at all growth stages.
• The filing of patent and trademark applications in the seed or early growth stage is associated with a higher likelihood of subsequent venture capital (VC) funding.
• The filing of applications for European patent and EU trademark is associated with an even higher likelihood of subsequent VC funding for startups (compared to just national IP rights).
• The filing of patent and/or trademark applications is associated with a more than twice as high likelihood of successful exit for investors.

In a significant legal development within the pharmaceutical landscape, Pfizer, the American pharmaceutical giant, has initiated a legal battle in Russia to claim over 12.5 billion rubles from Nativa, a company currently undergoing bankruptcy proceedings. This substantial claim is believed to encompass the financial losses that Pfizer asserts it incurred due to the sale of a generic version of its anti-tumor medication, sunitinib, by Nativa.
The indicated legal dispute between Pfizer and Nativa is rooted in the alleged patent infringement related to Sunitinib-Native, a generic version of Pfizer’s oncological drug, Sutent. Notably, Nativa began marketing this generic in 2017, while Pfizer’s patent for sunitinib, the active component within Sutent, was still in effect until August 31, 2022. Pfizer had previously engaged in legal disputes with Nativa over patent infringements, aiming to terminate the production and distribution of Sunitinib-Native. The court initially ruled in favor of Nativa, granting them a compulsory license for sunitinib in exchange for annual payments to Pfizer, amounting to 10% of the product’s sales revenue. It was only in October 2022 that Pfizer successfully challenged this decision on appeal.
In the most recent development, the court granted Pfizer Innovations’ request for information from Nativa about the quantity and pricing of Sunitinib-Native, which has been available in the market since March 2017. Sunitinib-Native has remarkably overtaken the original Sutent in sales since 2019 – 8.12 billion rubles vs 4.88 billion rubles through state procurement between 2018 and 2022.
Current complex patent dispute extends to Nativa’s prior legal conflicts with prominent pharmaceutical entities, including BMS, Celgene, and AstraZeneca. By the time bankruptcy proceedings were initiated, Nativa no longer held valid certificates for its pharmaceutical products. As a result, some of these certificates, including sunitinib, were transferred to Pharmmental Group in 2021.
In the legal battle with Pfizer, Nativa’s insolvency adds complexity to the case, raising questions about the practicality of recovering substantial damages.

According to international experts, the annual damage to global commercial aviation from bird strikes amounts to up to $1.2 billion. Engineers from the Vector Research Institute have received a Eurasian patent for a system that, using television, can prevent strikes even at poorly equipped airports.

The solution uses the digital broadcasting television center signals protecting equipment already installed on the territory of the airport from the effects of radar radiation.

The broadcasting center emits the digital broadcasting television signal. The signal is then reflected from the birds and received by surveillance channel antennas, and the direct signal from the broadcasting center is received by a reference channel antenna. The received signals are processed in the receiver. In case of a threat of collision, a threat processor launching the device of deterrence is activated.

The system provides autonomous operation, increases airport safety during the takeoff/landing of aircraft and reduces the number of false alarms.

Nationals and residents of the People’s Republic of China will continue to have the option to select the EPO as their International Searching Authority (ISA) for international patent applications filed in English under the Patent Cooperation Treaty (PCT) until 30 November 2026. This follows the success of the pilot scheme first started in December 2020, which is being extended for a further three years as mutually agreed between the European Patent Office (EPO) and the China National Intellectual Property Administration (CNIPA).
This extension enables nationals and residents of the People’s Republic of China to continue to obtain international searches and written opinions from the EPO, supporting their strategic objectives when considering patent protection in Europe. By using the EPO as their ISA, applicants can speed up the European patent grant process and save even more prosecution time if they request early entry into the European phase. Furthermore, they can save costs as neither a supplementary European search nor a translation of the PCT application would be required and the examination fee payable on entry into the European phase would be reduced by 75% when requesting international preliminary examination under PCT Chapter II with the EPO.
The decision to extend the scheme follows the pilot’s favourable evaluation by applicants, including enterprises, universities, research institutes, and private individuals. The capacity of the pilot remains set at 3 000 applications per year.

At the beginning of September, a major British-Swedish pharmaceutical group, AstraZeneca, made headlines by taking legal action in the Moscow Arbitration Court. They aim to dispute the Russian Ministry of Health’s decision regarding the approval of the oncology drug, Osimertinib, as submitted by Russian pharmaceutical firm Axelfarm.

Osimertinib is a substance invented by AstraZeneca and protected in Russia and Eurasian region by an Eurasian patent valid until 2032.

AstraZeneca considers the drug Osimertinib to be a reproduced pharmaceutical product (generic), meaning a drug with the same qualitative and quantitative composition of active ingredients as its pharmaceutical product Tagrisso, which is supplied to Russia.

The drug is indicated as a therapy for non-small cell lung cancer with EGFR gene mutations. According to data from the phase III ADAURA clinical trial, Osimertinib reduces the risk of recurrence or death by 80% when used as adjuvant therapy for the early stages of this type of cancer.

Axelfarm first submitted documents for the registration of Osimertinib in December 2020. In 2021, AstraZeneca claimed a violation of patent rights for Tagrisso. However, the company’s lawsuit remained unresolved. According to the court’s decision, the intention to register a generic cannot be considered a threat of patent rights infringement.

The preliminary hearing for this new case is scheduled for October 30th.

There were other legal precedents concerning Osimertinib, for example, in the USA AstraZeneca achieved favorable resolutions in its patent infringement litigations with Zydus Pharmaceuticals, Cadila Healthcare, MSN Laboratories, and MSN Pharmaceuticals in 2021 and with Alembic Pharmaceuticals in 2022.

In the meantime, AstraZeneca itself faced a different challenge concerning Tagrisso patents. This is because Puma Biotechnology and Pfizer’s Wyeth initiated their own lawsuit against AstraZeneca in 2022 for infringement of two US patents, the results of which are yet to be seen.

In 2023 Sony Interactive Entertainment Inc, the owner of PLAYSTATION trademarks, initiated multiple court cases against counterfeiters in the Russian Federation. The court recognized several cases of infringement of IP rights and awarded monetary compensation for sales of fake PLAYSTATION game consoles on popular marketplaces. Despite the currently limited presence in the market, many companies such as SONY continue to carefully monitor and combat illegal trademark use.

The Commercial Court Registry shows 27 cases initiated by Sony Interactive Entertainment Inc. in 2023 against various individuals in different regions of the country including 12 last August. That is a remarkable increase comparing to one case filed by Sony during the entire year of 2022. Some of the cases have already been decided in favor of Sony Interactive Entertainment satisfying the claims in full or partially. Some cases are based on trademark infringement while the decisions refer to illegal sale of PLAYSTATION gamepads on the widely used online platform Wildberries. Rapidly raising popularity of online retail platforms brings more counterfeit opportunities, so the marketplaces take actions to prevent and fight infringement. Wildberries, for example, introduced their own tool called digital arbitration.

Regarding Sony’s increase in court activity in comparison to the years preceding 2022, the reason could be legalization of parallel import which allowed third parties to import the goods labelled by brands that had left the Russian market. Although parallel import allows only genuine goods, once the borders have been opened for third party importers, the higher percentage of fake products calls for increased attention from the right holders.

Among other companies actively combatting IP rights infringement is Robert Bosch GmbH that has already filed 163 cases in 2023 and Harman International Industries Incorporated – the Samsung-owned company, holder of JBL trademarks – which is a Plaintiff in more than 430 court cases in Russia this year.

These numbers show that despite the unstable environment and suspension of activity many manufacturers and trademark holders find it important to keep the counterfeit level as low as possible and continue to carefully sustain their reputation for consumers.

The global easing of the regime of preventive measures against coronavirus infection after almost two years of the pandemic does not yet guarantee a regime of absolute calm. The COVID-19 virus and its evolving strains remain, although already familiar, still a significant threat.

Against this background, Russian scientists continue to protect with patents new methods for obtaining components of possible drugs for the prevention and treatment of coronavirus infection, improving both their effectiveness and reducing the cost of obtaining such components.
A new method for producing immunoglobulin G, for which Eurasian patent No. 044535 was issued in August, was developed by the National Immunobiological Company.
The process of obtaining a patented component includes the selection of donor plasma, alcohol fractionation of plasma to obtain precipitate II+III according to Cohn, dissolution of the resulting precipitate II+III in a buffer solution, viral solvent-detergent inactivation and chromatographic purification.
It was the use of blood components containing antibodies to SARS-CoV-2 that became one of the first solutions that doctors around the world proposed for the prevention and control of COVID-19. Over the long months of the pandemic, the proposed method has repeatedly proven its effectiveness, which also depended on the receipt of the starting components.
The method of Russian scientists, protected by a Eurasian patent, uses a simpler and more routine analytical method for collecting plasma samples – enzyme-linked immunosorbent assay (ELISA), which allows testing a large number of plasma samples in a short time.
The drug obtained according to the technology has a higher degree of viral safety compared to analogues and contains 6-22 times more diverse antibodies than the original plasma, which provides a wider range of antiviral activity and makes drugs based on immunoglobulin G much more effective.

Sir Patrick Vallance, the Government Chief Scientific Adviser, completed a review with proposals on pro-innovation regulation for digital technologies. In a response published on 15 March 2023, the Government acknowledged the urgent need to regulate the relationship between intellectual property and generative AI. The government is now working with users and rights holders on a code of practice on copyright and AI. The code of practice aims to make licences for data mining more available. It will help to overcome barriers that AI firms and users currently face, and ensure there are protections for rights holders. This ensures that the UK copyright framework promotes and rewards investment in creativity. It also supports the ambition for the UK to be a world leader in research and AI innovation.
The Intellectual Property Office invited industry representatives from the technology, creative and research sectors to form a working group. These sectors will help to ensure a balanced and pragmatic code of practice. It will enable both the AI and creative sectors to grow in partnership.
Working group meetings commenced on 5 June 2023. The government expects parties to enter into the final code of practice on a voluntary basis. If the code of practice is not adopted or agreement is not reached, legislation could be considered.